NOV 04, 2021 5:00 PM PDT

The first FDA approved eye drops to treat presbyopia and correct poor near-vision.

WRITTEN BY: J. Bryce Ortiz

Your Grandma’s favorite eyeglasses may soon find their way to the trashcan. Last Friday, October 29th, the United States Food and Drug Administration (FDA) approved for use the first-of-its-kind daily eyedrops to treat presbyopia, an eye condition that makes seeing close objects difficult. 

Presbyopia, from the Greek for “old eye,” is a common age-related loss of the eyes’ ability to focus on close objects and is caused when the lens of the eye becomes less flexible. In normal eyesight, the lens can change shape to help focus light onto the retina and this enables us to see things both up close and far away. But because the lens is more rigid in Presbyopia, the lens is unable to efficiently focus light on the retina leading to poor visual acuity with close objects. As such, as we age, many individuals rely on “reading” glasses to see nearby objects such as words in a book. Presbyopia affects close to 128 million Americans and begins to progress starting at the age of 40. The recent FDA approval of Vuity (pilocarpine HCl ophthalmic solution) is an exciting announcement for individuals who suffer from presbyopia. 

Vuity is the first and only FDA-approved eye drop to treat presbyopia and requires a once-daily eye drop to help with visual acuity. Vuity works by constricting the pupil of the eyes to enhance the depth of focus, while still maintaining pupillary response to various lighting conditions. Importantly, the drops work quickly (within 15 minutes) and last throughout the day. Dr. George Waring, Director of the Waring Vision Institute in South Carolina, stated that, “I am particularly encouraged by the rapid onset of action and duration of efficacy for Vuity to improve near and intermediate vision without impacting distance vision with one drop daily, particularly for those with mild to moderate presbyopia.”

The approval of Vuity by the FDA is based on recent clinical studies that evaluated the safety and efficacy of the eyedrops in patients with presbyopia. In the clinical trials, individuals with presbyopia were treated with Vuity once daily for 30 days and then given a visual assessment. When the patients treated with Vuity were compared to individuals who received placebo eyedrops, the data showed that Vuity led to statistically significant improvements in near-vision reading with very few adverse side effects. AbbVie, the pharmaceutical company that designed and manufacturers Vuity, is hoping to improve the lives of millions of individuals with this new eye drop. Michael Servino, vice chairman and president of AbbVie, said, “We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the way people and their eye doctors approach presbyopia.”

 

Sources: PrNewswireWebMDAmerican Academy of OphthalmologyInvestigative Ophthalmology and Visual Science

About the Author
Doctorate (PhD)
Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
DEC 02, 2022
Genetics & Genomics
Tips on Establishing a Reliable Cell Free DNA Workflow
Tips on Establishing a Reliable Cell Free DNA Workflow
Ever since its first discovery in 1948, circulating cell-free DNA (cfDNA) has captured the attention and imagination of ...
DEC 03, 2022
Neuroscience
Promising Epilepsy Treatment Suppresses Neuroinflammation
Promising Epilepsy Treatment Suppresses Neuroinflammation
A team of City University of Hong Kong (CityU) neuroscientists recently identified and developed a new drug candidate fo ...
JAN 19, 2023
Drug Discovery & Development
Introducing TruCytes™: The Ready-to-Use Immunophenotyping Control for Cell Therapy, Flow Cytometry and Beyond
Introducing TruCytes™: The Ready-to-Use Immunophenotyping Control for Cell Therapy, Flow Cytometry and Beyond
Are you a cell biologist, immunologist, or flow cytometrist? If so, you know how challenging it is to find quality contr ...
JAN 10, 2023
Neuroscience
A Human Drug Improves the Recall of Lost Memories in Mice
A Human Drug Improves the Recall of Lost Memories in Mice
Staying up all night to prepare for an exam may not be much help to students, because memory can be impaired by many thi ...
JAN 22, 2023
Neuroscience
Research Study Explores the Mysterious Causes of Pediatric Epilepsy
Research Study Explores the Mysterious Causes of Pediatric Epilepsy
Childhood epilepsy affects roughly 4% of the pediatric population, and there are many different types of epilepsy and se ...
JAN 29, 2023
Drug Discovery & Development
Introducing a plant toxin that can be used as an antibiotic: albicidin
Introducing a plant toxin that can be used as an antibiotic: albicidin
Albicidin is a peptide antibiotic that works as a DNA gyrase inhibitor with bactericidal activity towards fluoroquinolon ...
Loading Comments...